Skip to main content
Przejdź do strony domowej Komisji Europejskiej (odnośnik otworzy się w nowym oknie)
polski pl
CORDIS - Wyniki badań wspieranych przez UE
CORDIS

Development and Application of a New Class of Halogenated Reagents to Commercially Valuable Targets

Cel

The aim of this project is to expand upon a newly discovered platform reaction by developing new routes to Active Pharmaceutical Ingredients (APIs) Tolterodine and Ezetimibe and other advanced intermediates for the manufacture of drugs (i.e. benzylic fluorides and alcohols). It is planned that this platform will serve to enhance the competitveness of the European pharmaceutical manufacturing industry as it continues to face increased competition from other economies

In order to achieve this aim we need to bring together expertise in
(i) Organic Synthesis [Royal College of Surgeons in Ireland, “RCSI”]
(ii) Enantioselective fluorination [Nagoya University Japan, “Nagoya”]
(iii) Drug development and production [Integrated Research in Biotechnology & Medicine, “IRBM”]

To meet the aim we have divided the project into the following work packages:
WP1: Development of a new synthesis of Tolterodine.
WP2: Scale up of synthesis of Tolterodine.
WP3: Development of a new synthesis of Ezetimibe.
WP4: Scale up of synthesis of Ezetimibe.
WP5: Exemplification of alkoxylation to prepare enantiopure benzylic alcohols API intermediates
WP6: Preparation of benzylic fluorides
WP7: Management, Training, Dissemination & Communication

Dziedzina nauki (EuroSciVoc)

Program(-y)

Temat(-y)

System finansowania

MSCA-RISE - Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE)

Wyświetl wszystkie projekty finansowane w ramach tego programu finansowania

Zaproszenie do składania wniosków

(odnośnik otworzy się w nowym oknie) H2020-MSCA-RISE-2016

Wyświetl wszystkie projekty finansowane w ramach tego zaproszenia

Koordynator

ROYAL COLLEGE OF SURGEONS IN IRELAND
Wkład UE netto
€ 130 500,00
Koszt całkowity
€ 130 500,00

Uczestnicy (2)

Partnerzy (1)